50 Clarence Street
Suite 506 Level 5
Sydney, NSW 2000
Australia
61 2 9078 7671
https://www.bcaldiagnostics.com
Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Ms. Jayne Andrea Shaw | Co-Founder & Executive Chairman | 180k | N/D | N/D |
Hon. Ronald Anthony Phillips A.O. | Co-Founder & Non-Executive Director | 52,31k | N/D | N/D |
Dr. Amani Baterseh Ph.D. | Chief Scientist Officer | 338,91k | N/D | N/D |
Mr. Shane Ryan M.B.A. | Chief Executive Officer | N/D | N/D | N/D |
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICD | CFO & Company Secretary | N/D | N/D | 1953 |
Sean Kennedy | Director of Corporate Finance | N/D | N/D | N/D |
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
L'ISS Governance QualityScore di BCAL Diagnostics Limited al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.